• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.

作者信息

Cavallari L H, Beitelshees A L, Blake K V, Dressler L G, Duarte J D, Elsey A, Eichmeyer J N, Empey P E, Franciosi J P, Hicks J K, Holmes A M, Jeng Ljb, Lee C R, Lima J J, Limdi N A, Modlin J, Obeng A O, Petry N, Pratt V M, Skaar T C, Tuteja S, Voora D, Wagner M, Weitzel K W, Wilke R A, Peterson J F, Johnson J A

机构信息

Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.

Department of Medicine, University of Maryland, Baltimore, Maryland, USA.

出版信息

Clin Transl Sci. 2017 May;10(3):143-146. doi: 10.1111/cts.12456. Epub 2017 Mar 14.

DOI:10.1111/cts.12456
PMID:28294551
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5421730/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5f/5421730/f766b29053ba/CTS-10-143-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5f/5421730/f766b29053ba/CTS-10-143-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f5f/5421730/f766b29053ba/CTS-10-143-g001.jpg

相似文献

1
The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.IGNITE药物遗传学工作组：在现实环境中通过药物遗传学实施建立证据的契机。
Clin Transl Sci. 2017 May;10(3):143-146. doi: 10.1111/cts.12456. Epub 2017 Mar 14.
2
Interpreting and Implementing Clinical Pharmacogenetic Tests: Perspectives From Service Providers.解读与实施临床药物遗传学检测：服务提供者的观点
Clin Pharmacol Ther. 2019 Aug;106(2):298-301. doi: 10.1002/cpt.1494. Epub 2019 Jun 4.
3
What to expect from the Pharmacogenomics Research Network.药物基因组学研究网络的预期成果。
Clin Pharmacol Ther. 2011 Mar;89(3):339-41. doi: 10.1038/clpt.2010.293.
4
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.临床药物遗传学实施联盟指南（CPIC）：CYP2C9 与非甾体类抗炎药。
Clin Pharmacol Ther. 2020 Aug;108(2):191-200. doi: 10.1002/cpt.1830. Epub 2020 Apr 28.
5
Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.六个发达国家中已确立的与安全性相关的药物基因组学协会的健康监管沟通：一致性评估
Pharmacogenomics J. 2017 Mar;17(2):121-127. doi: 10.1038/tpj.2016.5. Epub 2016 Feb 23.
6
Are Randomized Controlled Trials Necessary to Establish the Value of Implementing Pharmacogenomics in the Clinic?在临床实践中，确定实施药物基因组学的价值是否需要随机对照试验？
Clin Pharmacol Ther. 2019 Aug;106(2):284-286. doi: 10.1002/cpt.1420. Epub 2019 Apr 12.
7
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.前瞻性临床药物遗传学实施：美国五个医疗中心的当前项目
Annu Rev Pharmacol Toxicol. 2015;55:89-106. doi: 10.1146/annurev-pharmtox-010814-124835. Epub 2014 Oct 2.
8
The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.表型标准化项目：改善严重药物不良反应的药物遗传学研究。
Clin Pharmacol Ther. 2011 Jun;89(6):784-5. doi: 10.1038/clpt.2011.30.
9
The National Institutes of Health Blueprint for Neuroscience Research.美国国立卫生研究院神经科学研究蓝图。
J Neurosci. 2006 Oct 11;26(41):10329-31. doi: 10.1523/JNEUROSCI.3979-06.2006.
10
Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.综合药物基因组学分析对院内处方的影响分析。
Pharmacogenet Genomics. 2019 Feb;29(2):23-30. doi: 10.1097/FPC.0000000000000346.

引用本文的文献

1
The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation.药物基因组学全球研究网络实施工作组：全球合作推进药物基因组学实施。
Pharmacogenet Genomics. 2025 Jan 1;35(1):1-11. doi: 10.1097/FPC.0000000000000547. Epub 2024 Oct 3.
2
One Step Ahead in Realizing Pharmacogenetics in Low- and Middle-Income Countries: What Should We Do?在低收入和中等收入国家实现药物遗传学方面领先一步：我们该怎么做？
J Multidiscip Healthc. 2024 Oct 23;17:4863-4874. doi: 10.2147/JMDH.S458564. eCollection 2024.
3
Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention.

本文引用的文献

1
Navigating pleiotropy in precision medicine: pharmacogenes from trauma to behavioral health.精准医学中的多效性应对：从创伤到行为健康的药物基因
Pharmacogenomics. 2016 Apr;17(5):499-505. doi: 10.2217/pgs.16.6. Epub 2016 Mar 29.
2
The IGNITE network: a model for genomic medicine implementation and research.IGNITE网络：基因组医学实施与研究的一个模型。
BMC Med Genomics. 2016 Jan 5;9:1. doi: 10.1186/s12920-015-0162-5.
3
A new initiative on precision medicine.一项关于精准医学的新倡议。
基因分型与接受经皮冠状动脉介入治疗的黑人患者氯吡格雷治疗的不良心血管结局相关。
J Am Heart Assoc. 2024 Jun 18;13(12):e033791. doi: 10.1161/JAHA.123.033791. Epub 2024 Jun 14.
4
A New Cloud-Native Tool for Pharmacogenetic Analysis.一种用于药物遗传学分析的新型云原生工具。
Genes (Basel). 2024 Mar 11;15(3):352. doi: 10.3390/genes15030352.
5
Impact of Pharmacogenomics in Clinical Practice.药物基因组学在临床实践中的影响。
Pharmaceuticals (Basel). 2023 Nov 13;16(11):1596. doi: 10.3390/ph16111596.
6
Medication reconciliation to support pharmacogenomics implementation.药物重整以支持药物基因组学的实施。
Ann Transl Med. 2022 Dec;10(23):1258. doi: 10.21037/atm-2022-57.
7
Building Evidence for Clinical Use of Pharmacogenomics and Reimbursement for Testing.为药物基因组学的临床应用建立证据及检测报销
Clin Lab Med. 2022 Dec;42(4):533-546. doi: 10.1016/j.cll.2022.09.009.
8
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y Inhibitor Prescribing After Percutaneous Coronary Intervention.经皮冠状动脉介入治疗后 CYP2C19 指导的 P2Y 抑制剂给药的潜在种族差异评估。
Clin Pharmacol Ther. 2023 Mar;113(3):615-623. doi: 10.1002/cpt.2776. Epub 2022 Nov 19.
9
Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians' attitudes to sociocultural differences between patients across the globe.临床精神病学中基因检测的障碍及其克服方法：从临床医生的态度到全球患者之间的社会文化差异。
Transl Psychiatry. 2022 Oct 11;12(1):442. doi: 10.1038/s41398-022-02203-6.
10
Evaluation of race and ethnicity disparities in outcome studies of genotype-guided antiplatelet therapy.基因分型指导抗血小板治疗结局研究中的种族和民族差异评估。
Front Cardiovasc Med. 2022 Aug 23;9:991646. doi: 10.3389/fcvm.2022.991646. eCollection 2022.
N Engl J Med. 2015 Feb 26;372(9):793-5. doi: 10.1056/NEJMp1500523. Epub 2015 Jan 30.
4
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.临床药物遗传学实施联盟 CYP2C19 基因型和氯吡格雷治疗指南：2013 年更新。
Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
5
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.CPIC：药物基因组学研究网络临床药物基因组学实施联盟。
Clin Pharmacol Ther. 2011 Mar;89(3):464-7. doi: 10.1038/clpt.2010.279. Epub 2011 Jan 26.